Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/docetaxel-fAzNPaFzZE
References (88)
-
J. Wanders, D. Schrijvers, U. Bruntsch (1993)
The EORTC-ECTG experience with acute hypersensitivity reactions in Taxotere studies [abstract]Proc Am Soc Clin Oncol, 12
-
C. Hudis, A. Seidman, J. Crown, C. Balmaceda, R. Freilich, T. Gilewski, T. Hakes, V. Currie, D. Lebwohl, J. Baselga, G. Raptis, M. Gollub, M. Robles, R. Bruno, L. Norton (1996)
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 1
-
E. Tomiak, J. Kerger, S. Lips (1992)
Unexpected pleural changes observed in patients treated with Taxotere (RP 56976): a new drug toxicity? [abstract]Ann Oncol, 3
-
G. Zimmerman, J. Keeling, H. Burris, Gayle Cook, R. Irvin, J. Kuhn, M. Mccollough, D. Hoff (1995)
Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent.Archives of dermatology, 131 2
-
I. Ringel, S. Horwitz (1991)
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.Journal of the National Cancer Institute, 83 4
-
S.B. Kaye (1995)
TaxoidsEur J Cancer A, 31A
-
M. Bissery, G. Nohynek, G. Sanderink, F. Lavelle (1995)
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.Anti-cancer drugs, 6 3
-
B. Braakhuis, B. Hill, M. Dietel, L. Kelland, M. Aapro, W. Zoli, P. Lelieveld (1994)
In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells.Anticancer research, 14 1A
-
M.S. Aapro, G. Zulian, P. Alberto (1992)
Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of taxotere [abstract no. 208]Ann Oncol, 3
-
V. Diéras, B. Chevallier, P. Kerbrat, I. Krakowski, H. Roché, J. Misset, M. Lentz, N. Azli, M. Murawsky, A. Riva, P. Pouillart, P. Fumoleau, European Cancer (1996)
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.British Journal of Cancer, 74
-
A. Commerçon, J. Bourzat, D. Bezard, M. Vuilhorgne (1994)
Partial synthesis of major human metabolites of docetaxelTetrahedron, 50
-
P.Z. New, R. Barohn (1993)
Neurotoxicity of Taxotere [abstract]Neurology, 43
-
P. Ravdin, H. Burris, Gayle Cook, P. Eisenberg, M. Kane, William Bierman, J. Mortimer, Eric Genevois, R. Bellet (1995)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
-
H. Burris, R. Irvin, J. Kuhn, S. Kalter, L. Smith, Don Shaffer, S. Fields, Geoffrey Weiss, J. Eckardt, G. Rodriguez (1993)
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 5
-
T. Taguchi, S. Mori, R. Abe (1994)
Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer [in Japanese]Gan to Kagaku Ryoho, 21
-
Richard Pazdur, Robert Newman, Beverly Newman, Angela Fuentes, J. Benvenuto, B. Bready, Dennis Moore, Ishmael Jaiyesimi, Franzanne Vreeland, M. Bayssas, Martin Raber (1992)
Phase I trial of Taxotere: five-day schedule.Journal of the National Cancer Institute, 84 23
-
B.T. Hill, R.D.H. Whelan, S.A. Shellard (1994)
Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitroInvest New Drugs, 12
-
J.E. Cortes, R. Pazdur (1995)
DocetaxelJ Clin Oncol, 13
-
K. McPherson, C.M. Steel, J.M. Dixon (1994)
Breast cancer-epidemiology, risk factors, and geneticsBMJ, 309
-
P. Hilkens, J. Verweij, G. Stoter, C. Vecht, W. Putten, M. Bent (1996)
Peripheral neurotoxicity induced by docetaxelNeurology, 46
-
T.-C. Chou, G.M. Otter, F.M. Sirotnak (1996)
Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitroCancer Chemother Pharmacol, 37
-
J. Díaz, J. Andreu (1993)
Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.Biochemistry, 32 11
-
Rubens Rd (1993)
Improving treatment for advanced breast cancer.Cancer surveys, 18
-
JF Riou, O Petitgenet, I Aynie (1994)
Establishment and characterization of docetaxel (Taxotere®) resistant human breast carcinoma (Calc18/TXT) and murine leukemic (P388/TXT) cell linesProceedings of the American Association Cancer Research, 35
-
P. Fumoleau, B. Chevallier, V. Dieras (1994)
Safety evaluation of two doses of Taxotere® (docetaxel) without routine premedication as first line in advanced breast cancer (ABC)-EORTC Clinical Screening Group (CSG) report [abstract]Proc Am Soc Clin Oncol, 13
-
D. Bissett, A. Setanoians, J. Cassidy, M. Graham, G. Chadwick, P. Wilson, V. Auzannet, N. Bail, S. Kaye, D. Kerr (1993)
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.Cancer research, 53 3
-
J.M. Andreu, J.F. Díaz, R. Gil (1994)
Solution structure of Taxotereinduced microtubules to 3-nm resolutionThe change in protofilament number is linked to the binding of the taxol side chain. J Biol Chem, 269
-
A.T. Oosterom, D. Schriivers (1995)
Docetaxel (Taxotere®), a review of preclinical and clinical experiencePart II: clinical experience. Anticancer Drugs, 6
-
G. Cavaletti, G. Tredici (1995)
Platinum compounds and taxoids: is combination neurotoxicity a possibility?Cancer J, 8
-
A. Hanauske, D. Degen, S. Hilsenbeck, M. Bissery, D. Hoff (1992)
Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cellsAnti-Cancer Drugs, 3
-
T. Taguchi, H. Furue, H. Niitani (1994)
Phase I clinical trial of RP56976 (docetaxel) a new anticancer drug [in Japanese]Gan to Kagaku Ryoho, 21
-
F. Marre, G. Sousa, M. Placidi (1993)
Élucidation des voies de biotransformation hépatique du Taxotère au moyen de modèles in vitro d’origine humaine [abstract]Bull Cancer, 80
-
J.T. Cole, R.J. Gralla, C.B. Marques (1995)
Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC) [abstract no1087]. Proc Am Soc Clin Oncol, 14
-
H. Burris, S. Fields, N. Peacock (1995)
Docetaxel (Taxotere) in combination: a step forward.Seminars in oncology, 22 6 Suppl 13
-
B. Chevallier, P. Fumoleau, P. Kerbrat, V. Diéras, H. Roché, I. Krakowski, N. Azli, M. Bayssas, M. Lentz, M. Glabbeke (1995)
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 2
-
T. Taguchi, S. Mori, R. Abe, K. Hasegawa, Y. Morishita, T. Tabei, Y. Sasaki, M. Fujita, K. Enomoto, K. Hamano (1994)
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer].Gan to kagaku ryoho. Cancer & chemotherapy, 21 15
-
A. Miller, B. Hoogstraten, M. Staquet, A. Winkler (1981)
Reporting results of cancer treatmentCancer, 47
-
M. Trudeau, E. Eisenhauer, B. Higgins, F. Letendre, W. Lofters, B. Norris, T. Vandenberg, F. Delorme, A. Muldal (1996)
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 2
-
M. Untch, A. Untch, B. Sevin, R. Angioli, J. Perras, O. Koechli, H. Averette (1994)
Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.Anti-cancer drugs, 5 1
-
C. Hennequin, N. Giocanti, V. Favaudon (1995)
S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells.British Journal of Cancer, 71
-
E.A. Eisenhauer, F. Lu, A. Muldal (1994)
Predictors and treatment of docetaxel (D) toxic effects [abstract]Ann Oncol, 5
-
J. Jaffrezou, G. Laurent (1995)
Drug Evaluation: Oncologic, Endocrine & Metabolic: Docetaxel (Taxotere®): current status and clinical prospectsExpert Opinion on Investigational Drugs, 4
-
C. Manthey, N. Qureshi, Peter Itz, S. Vogel (1993)
Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophagesThe Journal of Experimental Medicine, 178
-
T. Taguchi, H. Furue, H. Niitani, K. Ishitani, R. Kanamaru, K. Hasegawa, Y. Ariyoshi, K. Noda, K. Furuse, M. Fukuoka (1994)
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].Gan to kagaku ryoho. Cancer & chemotherapy, 21 12
-
M. Bissery, D. Guénard, F. Guéritte-Voegelein, F. Lavelle (1991)
Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.Cancer research, 51 18
-
J. Wanders, A. Oosterom, M. Gore (1993)
Taxotere toxicity — protective effects of premedication [abstract no. S206]Eur J Cancer, 29A
-
E. Tomiak, M. Piccart, J. Kerger, S. Lips, A. Awada, Dominique Valeriola, C. Ravoet, D. Lossignol, J. Sculier, V. Auzannet (1994)
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 7
-
J.R. Harris, M.E. Lippman, U. Veronesi (1992)
Breast cancer (first of three parts)N Engl J Med, 327
-
K. Gelmon (1994)
The taxoids: paclitaxel and docetaxelThe Lancet, 344
-
J. Riou, A. Naudin, F. Lavelle (1992)
Effects of Taxotere on murine and human tumor cell lines.Biochemical and biophysical research communications, 187 1
-
M.C. Bissery, P. Vrignaud, M. Bayssas (1994)
Docetaxel (RP 56976, Taxotere®) efficacy as a single agent or in combination against mammary tumors in mice [abstract no1946]. Proceedings of the American Association Cancer Research, 35
-
J.-M. Extra, F. Rousseau, R. Bruno (1993)
Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusionCancer Res, 53
-
I. Royer, Bernard Monsarrat, M. Sonnier, Michel Wright, Thierry Cresteil (1996)
Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs.Cancer research, 56 1
-
A. Oosterom, Dirk Schriivers (1995)
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.Anti-Cancer Drugs, 6
-
V. Dieras, P. Fumoleau, B. Chevallier (1994)
Second EORTC-Clinical Screening Group (CSG) phase II trial of Taxotere® (docetaxel) as first line chemotherapy in advanced breast cancer (ABC) [abstract]Proc Am Soc Clin Oncol, 13
-
José, AndreuSJ, J., Fernando Diazf, GilS, de PeredaS, Garcia Lacobal, Vincent Peymtll, Claudette Briandn, Elizabeth Towns-Andrewsll, Joan Bordasll (1994)
Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain.The Journal of biological chemistry, 269 50
-
D.J. Dykes, M.C. Bissery, S.D. Harrison (1995)
SD, et alResponse of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®). Invest New Drugs, 13
-
C. Spencer, D. Faulds (1994)
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.Drugs, 48 5
-
Early Group (1992)
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 womenThe Lancet, 339
-
Niraj Kumar (1981)
Taxol-induced polymerization of purified tubulin. Mechanism of action.The Journal of biological chemistry, 256 20
-
Cristina Lopes (2020)
RecurrentExercises in Programming Style
-
D. Oulid-Aïssa, A. Béhar, M. Spielmann (1994)
Management of fluid retention syndrome in patients treated with Taxotere® (docetaxel): effect of premedication [abstract]Proc Am Soc Clin Oncol, 13
-
J. Verweij, A.S.T. Planting, M.E.L. Burg (1994)
A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors [abstract no386]. Proc Am Soc Clin Oncol, 13
-
J. Zalcberg, J.F. Bishop, L.K. Webster (1994)
A phase I trial of the combination Taxotere (docetaxel) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) [abstract no. P773]Ann Oncol, 5
-
T. Taguchi (1994)
[An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract].Gan to kagaku ryoho. Cancer & chemotherapy, 21 14
-
C. Burkhart, J. Berman, C. Swindell, S. Horwitz (1994)
Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity.Cancer research, 54 22
-
C. Balmaceda, P. Forsyth, A.D. Seidman (1993)
Peripheral neuropathy in patients receiving taxotere chemotherapy [abstract]Ann Neurol, 34
-
N. Kumar (1981)
Taxol-induced polymerization of purified tubulinJ Biol Chem, 256
-
W. Zoli, A. Flamigni, G.L. Frassineti (1995)
In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancersBreast Cancer Res Treat, 34
-
M.C. Launay-Iliadis, R. Bruno, V. Cosson (1995)
Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimationCancer Chemother Pharmacol, 37
-
P. Fumoleau, B. Chevallier, P. Kerbrat, Y. Krakowski, J. Misset, C. Maugard-Louboutin, V. Diéras, N. Azli, N. Bougon, A. Riva, Henri Roché (1996)
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.Annals of oncology : official journal of the European Society for Medical Oncology, 7 2
-
M.J. Bent, P.H.E. Hilkens, J. Verwey (1995)
Docetaxel induces a mild dose-dependent sensory neuropathy [abstract]Neurology, 45
-
I. Adachi, T. Watanabe, S. Takashima (1996)
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerBr J Cancer, 73
-
G. Gruia, J.L. Misset, S. Giachetti (1995)
A phase I–II study of Taxotere (TXTR) in combination with Adriamycin (AD) as first line chemotherapy (CT) in patients with metastatic breast cancer [abstract no258]. Proc Am Soc Clin Oncol, 14
-
W. Huinink, A. Prové, M. Piccart, W. Steward, T. Tursz, J. Wanders, H. Franklin, M. Clavel, J. Verweij, M. Alakl, M. Bayssas, S. Kaye (1994)
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.Annals of oncology : official journal of the European Society for Medical Oncology, 5 6
-
G. Sledge, K. Antman (1992)
Progress in chemotherapy for metastatic breast cancer.Seminars in oncology, 19 3
-
D. Battafarano, G. Zimmerman, S. Older, J. Keeling, Howard Burn's (1995)
Docetaxel (Taxotere) associated scleroderma‐like changes of the lower extremities. A report of three casesCancer, 76
-
J.H.M. Schellens, J. Ma, R. Bruno (1994)
Pharmacokinetics of cisplatin and Taxotere® (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere®/cisplatin and cisplatin/Taxotere® in a phase I/II study in solid tumor patients [abstract]Proc Am Soc Clin Oncol, 13
-
V. Valero, F. Holmes, R. Walters, R. Theriault, L. Esparza, G. Fraschini, G. Fonseca, R. Bellet, A. Buzdar, G. Hortobagyi (1995)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
-
D. Valeriola, C. Brassinne, C. Gaillard (1993)
Study of excretion balance, metabolism and protein binding of C14radiolabelled Taxotere (TXT) (RP56976, NSC628503) in cancer patients [abstract no2221]. Proceedings of the American Association Cancer Research, 34
-
J.-P. Jaffrézou, G. Laurent (1995)
Docetaxel (Taxotere): current status and clinical prospectsExpert Opin Invest Drug, 4
-
M. Vogel, S. Hilsenbeck, H. Depenbrock, S. Danhauser‐Riedl, T. Block, H. Nekarda, C. Fellbaum, M. Aapro, M. Bissery, J. Rastetter (1993)
Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.European journal of cancer, 29A 14
-
L.R. Kelland, G. Abel (1992)
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell linesCancer Chemother Pharmacol, 30
-
M. Piccart, J. Klijn, R. Paridaens, M. Nooij, L. Mauriac, R. Coleman, A. Awada, J. Selleslags, A. Vreckem, M. Glabbeke (1995)
347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC)European Journal of Cancer, 31
-
F. Lavelle, M. Bissery, Cécile Combeau, J.-F. Riou, P. Vrignaud, S. André (1995)
Preclinical evaluation of docetaxel (Taxotere).Seminars in oncology, 22 2 Suppl 4
-
J. Harris, M. Lippman, Umberto Veronesi, Walter Willett (1992)
Breast cancer (1)The New England journal of medicine, 327 5
-
MC Bissery, P Vrignaud, M Bayssas (1993)
Taxotere® synergistic combination with cyclophosphamide, etoposide and 5-fluorouracil in mouse tumor modelsProceedings of the American Association Cancer Research, 34
-
Rene Bruno, G. Sanderink (1993)
Pharmacokinetics and metabolism of Taxotere (docetaxel).Cancer surveys, 17
- Publisher
- Springer Journals
- Copyright
- Copyright
- Subject
- Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
- ISSN
- 0012-6667
- eISSN
- 1179-1950
- DOI
- 10.2165/00003495-199651060-00011
- Publisher site
- See Article on Publisher Site
Abstract
Drugs 1996 Jun; 51 (6): 1075-1092 DRUG EVALUATION 0012-{J667/96/0006-1075/$18.00/0 © Adis International Umlted. All rights reserved. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Metastatic Breast Cancer Bret Fulton and Caroline M. Spencer Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: 1. Adachi, Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan; D. Bisset, Aberdeen Royal Hospitals NHS Trust, Aberdeen, Scotland; B.J.M. Braakhuis, Department of Otolaryngology/Head and Neck Surgery, Free University Hospital, Amsterdam, The Netherlands, EA. Eisenhauer, National Cancer Institute of Canada, Queen's University, Kingston, Ontario, Canada; G.N. Hortobagyi, Department of Breast and Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; CA. Hudis, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; 1.R. Judson, Department of Medical Oncology, CRC Centre for Cancer Therapeutics at The Institute of Cancer Research, Sutton, England; EM. Muggia, Division of Medical Oncology, Kenneth Norris Jr Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA; R. Pazdur, Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; M.J. Piccart, Unite de Chimiotherapie, Institut Jules Bordet, Brussels,
Journal
Drugs – Springer Journals
Published: Oct 31, 2012